BRCA1 and neoplasm: BRD4 inhibitors have been shown to suppressHR-associated genes, including CTIP, BRCA1,RAD51, and TOPBP1, thereby generating a state ofHR deficiency and synergy with PARPi.109,110 BET and PARP inhibitionhave demonstrated synergy in xenograft models with a reduction in tumor growth,increasing apoptosis, and DNA damage.111 Preclinically, BETinhibition has been shown to enhance antitumor immunity.112 A phaseI/Ib trial is evaluating the safety and efficacy of ZEN-3694, a BET inhibitor,plus nivolumab with or without ipilimumab in solid tumors, includingplatinum-resistant EOC (NCT04840589).